PLEASANTON, Calif,,
Feb. 22, 2022 /PRNewswire/ -- 10x
Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on
mastering biology to advance human health, today unveiled new
details about upcoming products and capabilities across its single
cell, spatial, and in situ platforms at its second annual Xperience
2022 virtual event. Highlights included the Fixed RNA Profiling
Kit, which improves sample preparation workflow and adds
flexibility for Chromium single cell experiments; Visium CytAssist,
to expand the number of tissue samples accessible to the spatial
platform; and the first-ever look at the forthcoming Xenium
Analyzer.
"Everything we do at 10x Genomics is driven by our belief that
in the not-too-distant future, most tissue samples will need to be
analyzed using the technologies we're developing across single
cell, spatial, and in situ," said Ben
Hindson, Co-Founder and Chief Scientific Officer of 10x
Genomics. "Our development engine is fired up, innovating,
executing, and collaborating to make 2022 the most exciting year of
product launches in our history. We're more than ready to build on
our track record of over 20 breakthrough technologies as we deliver
this year's unparalleled product pipeline."
For the Chromium single cell platform, Xperience 2022 featured
several upcoming products designed to enable broad adoption of
single cell methods, remove bottlenecks, and create more value for
researchers around the world:
- Chromium Fixed RNA Profiling - This kit, which combines
an entirely new chemistry and chip with formaldehyde fixation to
preserve biological state at the point of collection, enables
batching of samples for maximum study flexibility. (Planned to
launch in mid-2022.)
- Chromium Nuclei Isolation - This simple, scalable
product answers a major customer request. The kit allows for nuclei
isolation from frozen tissues, is easy to use, and requires no
expensive instruments (Planned to launch in mid-2022.)
- Chromium BEAM - Built on top of 10x's existing Immune
Profiling product, BEAM (Barcode Enabled Antigen Mapping) will make
it possible to perform high-throughput, high-plex, and
high-resolution mapping of antigen recognition by B or T cells.
(Planned to launch in late 2022.)
The single cell showcase also featured 5' CRISPR, an extension
to Single Cell Immune Profiling to make large-scale, functional
genomics studies quicker and easier; and ATAC v2, an update to the
Single Cell ATAC-seq workflow to boost sensitivity, while
increasing discovery power and reducing costs. Both are planned to
launch by mid-year.
Xperience 2022 also showcased the breadth of the Visium spatial
analysis product roadmap, featuring several upcoming technologies
focused on enabling more analytes, more samples, and more
resolution:
- Visium Gene and Protein Expression - This assay will
allow researchers to take a microscopy image of a stained FFPE
tissue section and then profile RNA and dozens of proteins
simultaneously in the same section at high spatial resolution.
(Planned to launch in mid-2022.)
- Visium CytAssist - A compact, benchtop instrument that
transfers analytes from tissue sections on standard glass slides to
Visium capture slides, CytAssist simplifies sample handling and
allows researchers to preview and select the best FFPE tissue
section for the Visium assay. (Planned to launch in mid-2022.)
- Visium HD - Providing a massive jump in resolution for
spatial analysis, the company expects that Visium HD will offer
unprecedented views of whole transcriptome data in heterogeneous
tissues at single cell scale resolution. (Planned to launch near
the end of 2022.)
Xperience 2022 provided a first look into Xenium, the
company's forthcoming in situ platform. The company expects the
Xenium Analyzer will deliver targeted gene expression information
at subcellular resolution at high sensitivity, and will be a
complete end-to-end in situ solution: a robust instrument,
consumables, panels, and software. Xenium is being developed as a
high throughput platform that can run large cohorts of entire
tissue sections without requiring selection of regions of interest.
10x Genomics expects to ship the Xenium Analyzer by the end of
2022.
"We plan to put the Xenium Analyzer in the hands of customers
this year, marking the beginning of a revolution in tissue
analysis, at the most fundamental level with unprecedented scale,"
Hindson added. "With our Xenium platform for in situ analysis, RNA
and proteins can be measured in the cells where they originated,
still located in the native tissue. Our multi-year roadmap will
usher in this powerful new capability and lead to an explosion of
new data and insights to ultimately master biology and advance
human health. Until then, we are relentlessly focused on this
mission."
To learn more about products showcased at Xperience 2022, please
visit
10xgenomics.com/new-products. The event will also be hosted on
February 24 for the Asia Pacific region, and registration is open
at 10xgenomics.com/xperience.
About 10x Genomics
10x Genomics is a life science technology company building
products to interrogate, understand and master biology to advance
human health. The company's integrated solutions include
instruments, consumables and software for analyzing biological
systems at a resolution and scale that matches the complexity of
biology. 10x Genomics products have been adopted by researchers
around the world including in all of the top 100 global research
institutions as ranked by Nature in 2020 based on publications and
all of the top 20 global pharmaceutical companies by 2020 research
and development spend and have been cited in over 3,300 research
papers on discoveries ranging from oncology to immunology and
neuroscience. The company's patent portfolio comprises more than
1,300 issued patents and patent applications.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange
Commission, its website (www.10xgenomics.com), press releases,
public conference calls, public webcasts and its social media
accounts as means of disclosing material non-public information and
for complying with its disclosure obligations under Regulation
FD.
Contacts
Media:
media@10xgenomics.com
Investors:
investors@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-showcases-robust-innovation-pipeline-at-xperience-2022-event-301487919.html
SOURCE 10x Genomics, Inc.